HemoShear Announces Next Stage of Safety Collaboration with Pfizer
News Jan 14, 2016
HemoShear Therapeutics, LLC (HemoShear) has announced that it would be initiating the next stage of a multi-year collaboration with Pfizer Inc. Under the terms of the agreement, which combines the scientific and technical expertise of both companies, HemoShear will leverage its proprietary discovery platform, REVEAL-Tx™, with the aim of developing a predictive model for preclinical drug-induced vascular injury (DIVI). Financial terms were not disclosed.
The initial stage of the collaboration between HemoShear and Pfizer was designed to assess the repeatability of vascular toxicities of a specifically chosen set of drugs in HemoShear’s REVEAL-Tx™ platform.
In this next stage, the companies will use HemoShear’s platform to assess a large number of compounds with the aim of building a predictive computational model that would be used for evaluation of vascular safety of Pfizer drug compounds before entering pre-clinical stages of development.
“Drug toxicity discovered in pre-clinical or clinical trials has serious implications for drug development,” said Jim Powers, Chief Executive Officer at HemoShear. “Our collaboration has the potential to create a new safety paradigm for the pharmaceutical industry that improves confidence in selecting safer drug candidates for pre-clinical trials, and we look forward to working with Pfizer to further develop this much needed, predictive model.”
DIVI poses a safety dilemma for the pharmaceutical industry because of limitations in resolving the underlying drivers of vascular injury. In addition, there are no generally accepted diagnostic or predictive biomarkers to understand when or why DIVI will occur, nor are there models to select the safest compound prior to animal testing.
If drug toxicity occurs in an animal, significant program delays and additional costs are incurred to investigate and explain the underlying biology and determine whether the compound is safe to move forward to human testing, or to determine if another compound would be safer. In some cases, decisions are made to stop a program altogether in the absence of a clear understanding of the injury and whether an animal response translates to human clinical outcomes.
In addition to leveraging REVEAL-Tx™ for safety and drug discovery collaborations with pharmaceutical companies, HemoShear Therapeutics is pursuing its own drug discovery programs in metabolic diseases with high unmet need.
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Microbiotica Enters into Microbiome Collaboration with GenentechNews
Strategic collaboration for microbiome biomarker signatures and therapeutic discovery based on Genentech’s inflammatory bowel disease pipeline.READ MORE